EFFICACY AND SAFETY OF BARICITINIB IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS AT 12 WEEKS

被引：0
|
作者：
Tanaka, Y. [1 ]
Emoto, K. [2 ]
Tsujimoto, M. [2 ]
Schlichting, D. [3 ]
Macias, W. [3 ]
机构：
[1] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[2] Eli Lilly Japan KK, Kobe, Hyogo, Japan
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1366
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0149
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY UP TO 24 WEEKS OF BARICITINIB FOR JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL WORLD MULTICENTER CLINICAL DATA
    Torikai, Eiji
    Suzuki, Daisuke
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 375 - 376
  • [2] The safety of baricitinib in patients with rheumatoid arthritis
    Honda, Suguru
    Harigai, Masayoshi
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 545 - 551
  • [3] Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase.
    Tanaka, Yoshiya
    Emoto, Kahaku
    Cai, Zhihong
    Schlichting, Douglas E.
    Rooney, Terence
    Macias, William
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S652 - S652
  • [4] Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
    Keystone, Edward C.
    Taylor, Peter C.
    Drescher, Edit
    Schlichting, Douglas E.
    Beattie, Scott D.
    Berclaz, Pierre-Yves
    Lee, Chin H.
    Fidelus-Gort, Rosanne K.
    Luchi, Monica E.
    Rooney, Terence P.
    Macias, William L.
    Genovese, Mark C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 333 - 340
  • [5] Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
    Fleischmann, Roy
    Alam, Jahangir
    Arora, Vipin
    Bradley, John D.
    Schlichting, Douglas E.
    Muram, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [6] Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
    Keystone, Edward C.
    Genovese, Mark C.
    Schlichting, Douglas E.
    de la Torre, Inmaculada
    Beattie, Scott D.
    Rooney, Terence P.
    Taylor, Peter C.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (01) : 14 - 21
  • [7] Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
    Kameda, Hideto
    Takeuchi, Tsutomu
    Yamaoka, Kunihiro
    Oribe, Motohiro
    Kawano, Mitsuhiro
    Yokoyama, Masayuki
    Pangan, Aileen L.
    Konishi, Yuko
    Meerwein, Sebastian
    Tanaka, Yoshiya
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [8] Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
    Hideto Kameda
    Tsutomu Takeuchi
    Kunihiro Yamaoka
    Motohiro Oribe
    Mitsuhiro Kawano
    Masayuki Yokoyama
    Aileen L. Pangan
    Yuko Konishi
    Sebastian Meerwein
    Yoshiya Tanaka
    Arthritis Research & Therapy, 23
  • [9] Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials
    Tanaka, Yoshiya
    Atsumi, Tatsuya
    Amano, Koichi
    Harigai, Masayoshi
    Ishii, Taeko
    Kawaguchi, Osamu
    Rooney, Terence P.
    Akashi, Naotsugu
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2018, 28 (04) : 583 - 591
  • [10] Efficacy of baricitinib on periodontal inflammation in patients with rheumatoid arthritis
    Ancuta, Codrina
    Pomirleanu, Cristina
    Mihailov, Claudia
    Chirieac, Rodica
    Ancuta, Eugen
    Iordache, Cristina
    Bran, Codruta
    Tanculescu, Oana
    JOINT BONE SPINE, 2020, 87 (03) : 235 - 239
12345